An appreciable number of patients with seizures are not helped by the standard anticonvulsants. There is, therefore, a constant search for new agents that will benefit this group. A new synthetic compound, primidone (Mysoline), has been made available to a number of investigators, and the results of four separate clinical trials had been reported at the time of writing.1 Handley and Stewart1a found this drug to be effective in 80% of 40 patients with grand mal seizures. In Butler's series1b of 58 patients with all types of seizures, there was improvement in 50% of patients with grand mal attacks. Smith and McNaughton1c were able to evaluate the results of primidone therapy in 61 patients and found that 35% were improved. Bonkalo and Arthurs1d reported on the use of primidone in the treatment of epileptic and nonepileptic psychiatric patients. They noted a reduction in the seizure